By Adriano Marchese
LifeMD on Thursday said it will integrate with Eli Lilly's online pharmacy and healthcare platform to offer access to Lilly's prescription obesity treatment Zepbound in single-dose vials.
LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.
Zepbound is available for on-label self-pay patients in vials with dosages between 2.5 milligrams and 10 milligrams through LillyDirect's self-pay pharmacy channel.
Recently, Lilly reduced the price of some offerings of its 2.5 and 5 milligram vials.
"This new integration complements our insurance-sponsored pharmacy programs, where we continue to see rising approval rates for branded GLP-1 therapies like Zepbound," LifeMD Chairman and Chief Executive Justin Schreiber said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 06, 2025 08:51 ET (13:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。